https://www.selleckchem.com/pr....oducts/tradipitant.h
These results collectively support the clinical evaluation of ABBV-744 in AML (Clinical Trials.gov identifier NCT03360006).Refractory Acute Myeloid Leukemia (AML) remains an incurable malignancy despite the clinical use of novel targeted therapies, new antibody-based therapies and cellular therapeutics. Here we describe the preclinical development of a novel cell therapy that targets the antigen CLEC12A with a biparatopic bridging protein. Bridging proteins are designed as "CAR-T cell engagers", with a CAR-targeted protein fused to
Like
Comment
Share
